SI3429559T1 - Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe - Google Patents

Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe

Info

Publication number
SI3429559T1
SI3429559T1 SI201631567T SI201631567T SI3429559T1 SI 3429559 T1 SI3429559 T1 SI 3429559T1 SI 201631567 T SI201631567 T SI 201631567T SI 201631567 T SI201631567 T SI 201631567T SI 3429559 T1 SI3429559 T1 SI 3429559T1
Authority
SI
Slovenia
Prior art keywords
flavor compositions
sodium phenylbutyrate
phenylbutyrate
sodium
flavor
Prior art date
Application number
SI201631567T
Other languages
English (en)
Slovenian (sl)
Inventor
Leah E. Appel
Joshua R. Shockey
D. Christopher SCHELLING
Original Assignee
Acer Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc. filed Critical Acer Therapeutics Inc.
Publication of SI3429559T1 publication Critical patent/SI3429559T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
SI201631567T 2016-03-15 2016-10-17 Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe SI3429559T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
EP16894786.9A EP3429559B1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Publications (1)

Publication Number Publication Date
SI3429559T1 true SI3429559T1 (sl) 2022-11-30

Family

ID=59847918

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631567T SI3429559T1 (sl) 2016-03-15 2016-10-17 Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe

Country Status (23)

Country Link
US (5) US20170266115A1 (enExample)
EP (2) EP4104822A1 (enExample)
JP (3) JP7136763B2 (enExample)
KR (3) KR20250150154A (enExample)
AU (1) AU2016398029B2 (enExample)
BR (1) BR112018068665B1 (enExample)
CA (1) CA3017573A1 (enExample)
CY (1) CY1125450T1 (enExample)
DK (1) DK3429559T3 (enExample)
ES (1) ES2922749T3 (enExample)
HR (1) HRP20220856T1 (enExample)
HU (1) HUE059630T2 (enExample)
IL (3) IL322955A (enExample)
LT (1) LT3429559T (enExample)
MX (2) MX391305B (enExample)
PL (1) PL3429559T3 (enExample)
PT (1) PT3429559T (enExample)
RS (1) RS63383B1 (enExample)
SA (1) SA518400020B1 (enExample)
SG (1) SG11201807979SA (enExample)
SI (1) SI3429559T1 (enExample)
SM (1) SMT202200386T1 (enExample)
WO (1) WO2017160345A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US20230248657A1 (en) * 2020-07-07 2023-08-10 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー-エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
MXPA06011765A (es) * 2004-04-12 2006-12-15 Pfizer Prod Inc Farmacos de sabor enmascarado en multiparticulados que se rompen.
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
JP4706785B2 (ja) * 2008-09-30 2011-06-22 アステラス製薬株式会社 経口投与用粒子状医薬組成物
BR112012001465B1 (pt) * 2009-07-24 2021-08-31 Baylor College Of Medicine Uso de um fenilbutirato, sal, éster ou pró-fármaco do mesmo
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
US20130323362A1 (en) 2010-12-06 2013-12-05 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
US20140178484A1 (en) * 2011-05-16 2014-06-26 Sun Pharma Advanced Research Company Ltd. Multi-particulate pharmaceutical composition
WO2012168882A1 (en) 2011-06-07 2012-12-13 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
RU2014100048A (ru) 2011-06-22 2015-07-27 Гмп-Орфан Соль 4-фенилбитурата, предназначенная для лечения болезни моторных нейронов или метаболического заболевания при ректальном введении
EP3318247A1 (en) * 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN105560203A (zh) 2013-01-28 2016-05-11 万平 定位速释生物粘附剂及其制备方法和应用
JP6147711B2 (ja) 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.

Also Published As

Publication number Publication date
US20210220304A1 (en) 2021-07-22
IL261777A (en) 2018-10-31
PL3429559T3 (pl) 2022-11-07
EP3429559B1 (en) 2022-04-13
KR20190008840A (ko) 2019-01-25
EP4104822A1 (en) 2022-12-21
WO2017160345A8 (en) 2018-02-22
AU2016398029B2 (en) 2023-03-02
MX391305B (es) 2025-03-21
MX2018011229A (es) 2019-05-30
US11433041B2 (en) 2022-09-06
IL261777B (en) 2022-10-01
LT3429559T (lt) 2022-08-10
CY1125450T1 (el) 2025-05-09
US20200261385A1 (en) 2020-08-20
US20210186908A1 (en) 2021-06-24
SMT202200386T1 (it) 2022-11-18
KR102690703B1 (ko) 2024-08-02
SA518400020B1 (ar) 2022-12-21
JP2022106927A (ja) 2022-07-20
JP7136763B2 (ja) 2022-09-13
US11154521B2 (en) 2021-10-26
IL322955A (en) 2025-10-01
PT3429559T (pt) 2022-07-20
BR112018068665A2 (pt) 2019-02-05
HUE059630T2 (hu) 2022-11-28
SG11201807979SA (en) 2018-10-30
RS63383B1 (sr) 2022-08-31
US20230133629A1 (en) 2023-05-04
CA3017573A1 (en) 2017-09-21
WO2017160345A1 (en) 2017-09-21
EP3429559A1 (en) 2019-01-23
HRP20220856T1 (hr) 2022-10-14
BR112018068665B1 (pt) 2023-12-26
US11202767B2 (en) 2021-12-21
AU2016398029A1 (en) 2018-10-11
MX2022003969A (es) 2022-04-25
JP2024081748A (ja) 2024-06-18
DK3429559T3 (da) 2022-07-11
IL296490B1 (en) 2025-09-01
KR102865751B1 (ko) 2025-09-29
JP2019509345A (ja) 2019-04-04
IL296490A (en) 2022-11-01
ES2922749T3 (es) 2022-09-20
EP3429559A4 (en) 2019-11-06
IL261777B2 (en) 2023-02-01
KR20240119184A (ko) 2024-08-06
KR20250150154A (ko) 2025-10-17
US20170266115A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
SI3607069T1 (sl) Produkti in sestavki
PL3694286T3 (pl) Ramki wyzwalające przystosowane do reguł opartych na pakietach w sieci 802.11
PL3628691T3 (pl) Amfifilowe pochodne polisacharydów i zawierające je kompozycje
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
SI3347472T1 (sl) Sestavki, ki obsegajo polipeptide klada CYP76AD1, in uporabe le-teh
IL247836B (en) 1, 3-benzodioxole derivatives, preparations containing them and their uses
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
SI3429559T1 (sl) Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe
PL3269257T3 (pl) Kompozycja słodzika i żywność ją zawierająca
DK3782617T3 (da) Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon
SI3319948T1 (sl) Sestavki kalijevega acesulfama in postopek za izdelavo le-teh
IL284242A (en) Gingerpine lysine suppressants, preparations containing them and their uses
PL3135110T3 (pl) Pochodne 1,7-diarylo-1,6-heptadieno-3,5-dionu, sposób ich wytwarzania i ich zastosowanie
SI3169307T1 (sl) Vodni pripravek, ki vsebuje paracetamol in ibuprofen
FR3029915B1 (fr) Tripeptides, compositions les comprenant et utilisations notamment cosmetiques
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
SI3337506T1 (sl) Kombinacije in njihove uporabe
PL3370522T3 (pl) Środek przeciwdrobnoustrojowy zawierający ksantohumol i jego stosowanie w produktach spożywczych
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3266310T3 (da) Nukleotidsammensætning og anvendelse i fødevare deraf
IL262119A (en) Storage stable food compositions